The sixth meeting of the EECA CAB
Apskatīt komentārus (0)


09.07.2014

---

In particular, Patent Pool provided information about licensing agreements covering dolutegravir, atazanavir and valganciclovir; discussed the mechanism of granting voluntary licenses for the generic drugs manufacturing. Position of the activists in regards to Patent Pool: improving of geographic coverage of existing and future agreements should include all EECA countries, taking into account the high burden of the HIV and hepatitis C in the region.

Pharmasyntez: a portfolio of generic ARVs of the company, quality issues, as well as registration and pricing policy in Russia and the region were discussed.

Janssen: information on the use of company’s drugs in clinical practice (darunavir, etravirine, rilpivirine, "Eviplera", simeprevir), as well as the company's policy on access to the drugs in EECA countries were discussed.

BMS: results of the third phase of clinical trials for hepatitis C treatment (daclatasvir, asunaprevir, pegylated interferon lambda), plans to conduct clinical trials and early access programs in the region, as well as policies on access to medicines were discussed.

MSD: a review of recent data of clinical trials of hepatitis C drugs; plans for clinical trials in the EECA region, price and registration policies in the region in regards to boceprevir and pegylated interferon alfa-2b.

Detailed minutes of the meetings will be available on the EECA CAB web-site in early August.
EECA CAB